ALLISON BERTRAND: Open Payments
NPI 1295010288 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,526 in 69 payments from 21 companies in 2025. Trend: 2023 $1,265 · 2024 $1,463 · 2025 $1,526
Food & beverage: $1,526
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $346 |
| PFIZER INC. | 11 | $219 |
| ABBVIE INC. | 6 | $215 |
| E.R. Squibb & Sons, L.L.C. | 6 | $117 |
| Daiichi Sankyo Inc. | 4 | $101 |
| Celgene Corporation | 5 | $94 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| ARRAY BIOPHARMA INC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Gilead Sciences, Inc. | 2 | $34 |
Products named: ELAHERE, Enhertu, OPDIVO, REBLOZYL, Fabhalta, IBRANCE, KISQALI, KEYTRUDA.
Industry payments across LA — which companies pay providers there.
